


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A compound of the Formula (I-1):



I-1

wherein:

X is alkylene optionally interrupted by one or more -O- groups;

Z is -C(O)-, -C(O)O-, or -C(Q R\_{1-2})\_2-;

R\_{1-1} is selected from the group consisting of:

hydrogen,

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl,

-N(CH\_3)(OCH\_3), and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,  
 haloalkoxy,  
 alkyl,  
 $\text{-NH-SO}_2\text{-R}_{1-4}$ ,  
 $\text{-NH-C(O)-R}_{1-4}$ ,  
 $\text{-NH-C(O)-NH}_2$ ,  
 $\text{-NH-C(O)-NH-R}_{1-4}$ , and  
 $\text{-N}_3$ ;

with the proviso that if Z is  $\text{-C(O)-}$ , then  $\text{R}_{1-4}$  may also be

~~$\text{-N(CH}_3\text{)(OCH}_3\text{)}$ ;~~

with the further proviso that if Z is  $\text{-C(O)O-}$ , then  $\text{R}_{1-4}$  is not hydrogen;

with the further proviso that if Z is  $\text{-C(O)O-}$ , then X does not include  $\text{-O-}$  groups;

Q is O or S;

$\text{R}_{1-3}$  is selected from the group consisting of:

alkyl,  
 aryl,  
 alkylene-aryl,  
 heteroaryl,  
 alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen;  
 cyano;  
 nitro;  
 alkoxy;  
 dialkylamino;  
 alkylthio;  
 haloalkyl;  
 haloalkoxy;  
 alkyl;  
 $\text{-NH-SO}_2\text{-R}_{1-4}$ ;

~~\_\_\_\_\_NH-C(O)-R<sub>1-4</sub>;~~  
~~\_\_\_\_\_NH-C(O)-NH<sub>2</sub>;~~  
~~\_\_\_\_\_NH-C(O)-NH-R<sub>1-4</sub>; and~~  
~~\_\_\_\_\_N<sub>3</sub>;~~

or the R<sub>1-4</sub> groups can join together to form a ring system comprising a saturated or unsaturated 5-, 6-, or 7-membered ring;

R<sub>1-4</sub> is selected from the group consisting of:

alkyl,  
 aryl,  
 alkylene-aryl,  
 heteroaryl,  
 alkylene-heteroaryl, and  
 alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,  
 cyano,  
 nitro,  
 alkoxy,  
 dialkylamino,  
 alkylthio,  
 haloalkyl,  
 haloalkoxy,  
 alkyl, and  
 -N<sub>3</sub>; and






R<sub>2</sub> is selected from the group consisting of:

-R<sub>4</sub>,  
 -X'-R<sub>4</sub>,  
 -X'-Y'-R<sub>4</sub>, and  
 -X'-R<sub>5</sub>;


X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, and heteroarylene, wherein the alkylene, alkenylene, and alkynylene groups can be optionally

interrupted or terminated with arylene, or heteroarylene, and optionally interrupted by one or more -O- groups;

Y' is selected from the group consisting of:



, and



R<sub>4</sub> is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, and alkylheteroarylenyl, wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, and alkylheteroarylenyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, and alkynyl, oxo;



$-N(R_9)_2$ ; and

$R_9$  is selected from the group consisting of:

halogen,

hydroxy,

alkyl,

alkenyl,

haloalkyl,


alkoxy,

alkylthio, and

$-N(R_9)_2$ ;

or a pharmaceutically acceptable salt thereof.

2. (currently amended) A compound of the Formula (I-2):



I-2

wherein:

X is alkylene optionally interrupted by one or more -O- groups;

n is an integer from 0 to 4;

Z is  $-C(O)-$ ,  $-C(O)O-$ , or  $-C(Q R_{1-3})_2-$ ;

$R_{1-1}$  is selected from the group consisting of:

hydrogen,

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl,

$-N(CH_3)(OCH_3)$ , and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,  
 cyano,  
 nitro,  
 alkoxy,  
 dialkylamino,  
 alkylthio,  
 haloalkyl,  
 haloalkoxy,  
 alkyl,  
 $-\text{NH}-\text{SO}_2-\text{R}_{1-4}$ ,  
 $-\text{NH}-\text{C}(\text{O})-\text{R}_{1-4}$ ,  
 $-\text{NH}-\text{C}(\text{O})-\text{NH}_2$ ,  
 $-\text{NH}-\text{C}(\text{O})-\text{NH}-\text{R}_{1-4}$ , and  
 $-\text{N}_3$ ;

with the proviso that if Z is  $-\text{C}(\text{O})-$ , then  $\text{R}_{1-4}$  may also be

$-\text{N}(\text{CH}_3)(\text{OCH}_3)$ ;

with the further proviso that if Z is  $-\text{C}(\text{O})\text{O}-$ , then  $\text{R}_{1-4}$  is not hydrogen;

with the further proviso that if Z is  $-\text{C}(\text{O})\text{O}-$ , then X does not include  $-\text{O}-$  groups;

\_\_\_\_\_ Q is O or S;

$\text{R}_{1-4}$  is selected from the group consisting of:

alkyl,  
 aryl,  
 alkylene-aryl,  
 heteroaryl,  
 alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

\_\_\_\_\_ halogen,  
 \_\_\_\_\_ cyano,

\_\_\_\_\_ nitro,  
 \_\_\_\_\_ alkoxy,  
 \_\_\_\_\_ dialkylamino,  
 \_\_\_\_\_ alkylthio,  
 \_\_\_\_\_ haloalkyl,  
 \_\_\_\_\_ haloalkoxy,  
 \_\_\_\_\_ alkyl,  
 \_\_\_\_\_  $\text{NH-SO}_2\text{-R}_{1-4}$ ,  
 \_\_\_\_\_  $\text{NH-C(O)-R}_{1-4}$ ,  
 \_\_\_\_\_  $\text{NH-C(O)-NH}_2$ ,  
 \_\_\_\_\_  $\text{NH-C(O)-NH-R}_{1-4}$ , and  
 \_\_\_\_\_  $\text{-N}_2$ ;

or the  $\text{R}_{1-2}$  groups can join together to form a ring system comprising a saturated or unsaturated 5-, 6-, or 7-membered ring;

$\text{R}_{1-4}$  is selected from the group consisting of:

alkyl,  
 aryl,  
 alkylene-aryl,  
 heteroaryl,  
 alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,  
 cyano,  
 nitro,  
 alkoxy,  
 dialkylamino,  
 alkylthio,  
 haloalkyl,  
 haloalkoxy,  
 alkyl, and



$-\text{N}_3$ ; and

R is selected from the group consisting of:

fluoro,  
alkyl,  
haloalkyl,  
alkoxy, and  
 $-\text{N}(\text{R}_9)_2$ ;


$\text{R}_2$  is selected from the group consisting of:


$-\text{R}_4$ ,  
 $-\text{X}'\text{-R}_4$ ,  
 $-\text{X}'\text{-Y}'\text{-R}_4$ , and  
 $-\text{X}'\text{-R}_5$ ;

$\text{X}'$  is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, and heteroarylene, wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene or heteroarylene, and optionally interrupted by one or more  $-\text{O}-$  groups;

$\text{Y}'$  is selected from the group consisting of:


$-\text{S}(\text{O})_{0-2}-$ ,  
 $-\text{S}(\text{O})_2\text{-N}(\text{R}_8)-$ ,  
 $-\text{C}(\text{R}_6)-$ ,  
 $-\text{C}(\text{R}_6)\text{-O}-$ ,  
 $-\text{O-C}(\text{R}_6)-$ ,  
 $-\text{O-C}(\text{O})\text{-O}-$ ,  
 $-\text{N}(\text{R}_8)\text{-Q}'-$ ,  
 $-\text{C}(\text{R}_6)\text{-N}(\text{R}_8)-$ ,  
 $-\text{O-C}(\text{R}_6)\text{-N}(\text{R}_8)-$ ,  
 $-\text{C}(\text{R}_6)\text{-N}(\text{OR}_9)-$ ,





R<sub>4</sub> is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, and alkylheteroarylenyl, wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, and alkylheteroarylenyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, and alkynyl, oxo;

$R_5$  is selected from the group consisting of:



$R_6$  is selected from the group consisting of =O and =S;

R<sub>7</sub> is a C<sub>2-7</sub> alkylene;

R<sub>8</sub> is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

R<sub>9</sub> is selected from the group consisting of hydrogen and alkyl;

R<sub>10</sub> is C<sub>3-8</sub> alkylene;

A is selected from the group consisting of -O-, -C(O)-, -S(O)<sub>0-2</sub>-, -CH<sub>2</sub>-, and -N(R<sub>4</sub>)-;


Q' is selected from the group consisting of a bond,  $-C(R_6)-$ ,  $-C(R_6)-C(R_6)-$ ,  $-S(O)_2-$ , and  $-S(O)_2-N(R_8)-$ ;

V is selected from the group consisting of -C(R<sub>6</sub>)-, -O-C(R<sub>6</sub>)-, and -S(O)<sub>2</sub>-; and

a and b are independently integers from 1 to 6 with the proviso that  $a + b$  is  $\leq 7$ ;

or a pharmaceutically acceptable salt thereof.

3. (currently amended) A compound of the Formula (I-3):



I-3

wherein:

X is alkylene optionally interrupted by one or more -O- groups;

Z is -C(O)-, -C(O)O-, or -C(-Q-R<sub>1-3</sub>)<sub>2</sub>;

R<sub>1-1</sub> is selected from the group consisting of:

hydrogen,

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl,

-NH-SO<sub>2</sub>-R<sub>1-4</sub>,

-NH-C(O)-R<sub>1-4</sub>,

-NH-C(O)-NH<sub>2</sub>,

-NH-C(O)-NH-R<sub>1-4</sub>, and

-N<sub>3</sub>;

with the proviso that if Z is -C(O)-, then R<sub>1-1</sub> may also be

-N(CH<sub>3</sub>)(OCH<sub>3</sub>);

with the further proviso that if Z is -C(O)O-, then R<sub>1-1</sub> is not hydrogen;

with the further proviso that if Z is -C(O)O-, then X does not include -O- groups;

Q is O or S;

R<sub>1-3</sub> is selected from the group consisting of:

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl,

-NH-SO<sub>2</sub>-R<sub>1-4</sub>,

-NH-C(O)-R<sub>1-4</sub>,

-NH-C(O)-NH<sub>2</sub>,

-NH-C(O)-NH-R<sub>1-4</sub>, and

-N<sub>3</sub>;

or the  $R_{1-3}$  groups can join together to form a ring system comprising a saturated or unsaturated 5-, 6-, or 7-membered ring;

$R_{1-4}$  is selected from the group consisting of:

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl, and

$-N_3$ ; and

$R_2$  is selected from the group consisting of:

$-R_4$ ,

$-X'-R_4$ ,







$-X'-Y'-R_4$ , and

$-X'-R_5$ ;

$X'$  is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, and heteroarylene, wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene or heteroarylene, and optionally interrupted by one or more  $-O-$  groups;


$Y'$  is selected from the group consisting of:

$-S(O)_{0-2}$ ,



$R_4$  is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, and alkylheteroarylenyl, wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, and alkylheteroarylenyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, and alkynyl, oxo;

$R_5$  is selected from the group consisting of:



$R_6$  is selected from the group consisting of =O and =S;

R<sub>7</sub> is a C<sub>2-7</sub> alkylene;

R<sub>8</sub> is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

R<sub>9</sub> is selected from the group consisting of hydrogen and alkyl;

R<sub>10</sub> is C<sub>3-8</sub> alkylene;

A is selected from the group consisting of -O-, -C(O)-, -S(O)<sub>0-2</sub>-, -CH<sub>2</sub>-, and -N(R<sub>4</sub>)-

Q' is selected from the group consisting of a bond, -C(R<sub>6</sub>)-, -C(R<sub>6</sub>)-C(R<sub>6</sub>)-, -S(O)<sub>2</sub>-, and -S(O)<sub>2</sub>-N(R<sub>8</sub>)-

V is selected from the group consisting of -C(R<sub>6</sub>)-, -O-C(R<sub>6</sub>)-, and

a and b are independently integers from 1 to 6 with the proviso that a + b is ≤ 7; and

R<sub>A'</sub> and R<sub>B'</sub> are each independently selected from the group consisting of:

hydrogen,

halogen,

alkyl,

alkenyl,

alkoxy,


alkylthio, and

-N(R<sub>9</sub>)<sub>2</sub>;

or a pharmaceutically acceptable salt thereof.

4. (canceled)

5. (original) A compound of the Formula (Ia):



Ia

wherein:

X is alkylene optionally interrupted by one or more -O- groups;

n is an integer from 0 to 4;

R<sub>1-1</sub> is selected from the group consisting of:

hydrogen,

alkyl,

aryl,

alkylenc-aryl,

heteroaryl,

alkylene-heteroaryl,

-N(CH<sub>3</sub>)(OCH<sub>3</sub>), and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl,

-NH-SO<sub>2</sub>-R<sub>1-4</sub>,

-NH-C(O)-R<sub>1-4</sub>,

-NH-C(O)-NH<sub>2</sub>,

-NH-C(O)-NH-R<sub>1-4</sub>, and

-N<sub>3</sub>;

R<sub>1-4</sub> is selected from the group consisting of:

alkyl,

aryl,

alkylenc-aryl,



heteroaryl,  
alkylene-heteroaryl, and  
alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,  
cyano,  
nitro,  
alkoxy,  
dialkylamino,  
alkylthio,  
haloalkyl,  
haloalkoxy,  
alkyl, and  
-N<sub>3</sub>;

R is selected from the group consisting of:

fluoro,  
alkyl,  
haloalkyl,  
alkoxy, and  
-N(R<sub>9</sub>)<sub>2</sub>;

R<sub>2</sub> is selected from the group consisting of:

hydrogen,  
alkyl,  
alkenyl,  
aryl,  
heteroaryl,  
heterocyclyl,  
alkylene-Y-alkyl,  
alkylene-Y-alkenyl,  
alkylene-Y-aryl, and

alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

hydroxy,  
halogen,  
-N(R<sub>3</sub>)<sub>2</sub>,  
-C(O)-C<sub>1-10</sub>alkyl,  
-C(O)-O-C<sub>1-10</sub>alkyl,  
-N(R<sub>3</sub>)-C(O)-C<sub>1-10</sub>alkyl,  
-N<sub>3</sub>,  
aryl,  
heteroaryl,  
heterocyclyl,  
-C(O)-aryl, and  
-C(O)-heteroaryl;

wherein:

Y is -O- or -S(O)<sub>0-2</sub>;


R<sub>3</sub> is selected from the group consisting of:

hydrogen,  
C<sub>1-10</sub>alkyl, and  
C<sub>2-10</sub>alkenyl; and

R<sub>9</sub> is selected from the group consisting of hydrogen and alkyl;  
or a pharmaceutically acceptable salt thereof.

6. (canceled)

7. (original) A compound of the Formula (Id):



Id

wherein:

X is alkylene optionally interrupted by one or more -O- groups;

n is an integer from 0 to 4;

$\text{R}_{1-1}$  is selected from the group consisting of:

hydrogen,

alkyl,

aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl,

$-\text{NH}-\text{SO}_2-\text{R}_{1-4}$ ,

$-\text{NH}-\text{C}(\text{O})-\text{R}_{1-4}$ ,

-NH-C(O)-NH<sub>2</sub>,  
-NH-C(O)-NH-R<sub>1-4</sub>, and  
-N<sub>3</sub>;

Q is O or S;

R<sub>1-3</sub> is selected from the group consisting of:

alkyl,  
aryl,  
alkylene-aryl,  
heteroaryl,  
alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,  
cyano,  
nitro,  
alkoxy,  
dialkylamino,  
alkylthio,  
haloalkyl,  
haloalkoxy,  
alkyl,  
-NH-SO<sub>2</sub>-R<sub>1-4</sub>,  
-NH-C(O)-R<sub>1-4</sub>,  
-NH-C(O)-NH<sub>2</sub>,  
-NH-C(O)-NH-R<sub>1-4</sub>, and  
-N<sub>3</sub>;

or the R<sub>1-3</sub> groups can join together to form a ring system comprising a saturated or unsaturated 5-, 6-, or 7-membered ring;

R<sub>1-4</sub> is selected from the group consisting of:

alkyl,  
aryl,

alkylene-aryl,

heteroaryl,

alkylene-heteroaryl, and

alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene-heteroaryl substituted by one or more substituents selected from the group consisting of:

halogen,

cyano,

nitro,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy,

alkyl, and

-N<sub>3</sub>;

R is selected from the group consisting of:

fluoro,

alkyl,

alkoxy,

haloalkyl, and

-N(R<sub>9</sub>)<sub>2</sub>;

R<sub>2</sub> is selected from the group consisting of:

hydrogen,

alkyl,

alkenyl,

aryl,

heteroaryl,

heterocyclyl,

alkylene-Y-alkyl,

alkylene-Y-alkenyl,

alkylene-Y-aryl, and

alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

hydroxy,  
 halogen,  
 $-N(R_3)_2$ ,  
 $-C(O)-C_{1-10}alkyl$ ,  
 $-C(O)-O-C_{1-10}alkyl$ ,  
 $-N(R_3)-C(O)-C_{1-10}alkyl$ ,  
 $-N_3$ ,  
 aryl,  
 heteroaryl,  
 heterocyclyl,  
 $-C(O)-aryl$ , and  
 $-C(O)-heteroaryl$ ;

wherein:


Y is  $-O-$  or  $-S(O)_{0.2-}$ ; and

$R_3$  is selected from the group consisting of:

hydrogen,  
 $C_{1-10}alkyl$ , and  
 $C_{2-10}alkenyl$ ; and

$R_9$  is selected from the group consisting of hydrogen and alkyl;  
 or a pharmaceutically acceptable salt thereof.

8. (original) A compound of the Formula (Ic):



Ic

wherein:

X is alkylene optionally interrupted by one or more -O- groups;

n is an integer from 0 to 4;

R is selected from the group consisting of:

fluoro,  
alkyl,  
alkoxy,  
haloalkyl, and  
-N(R<sub>9</sub>)<sub>2</sub>;

R<sub>2</sub> is selected from the group consisting of:

hydrogen,  
alkyl,  
alkenyl,  
aryl,  
heteroaryl,  
heterocyclyl,  
alkylene-Y-alkyl,  
alkylene-Y-alkenyl,  
alkylene-Y-aryl, and  
alkyl or alkenyl substituted by one or more substituents selected from the group

consisting of:

hydroxy,  
halogen,  
-N(R<sub>3</sub>)<sub>2</sub>,  
-C(O)-C<sub>1-10</sub>alkyl,  
-C(O)-O-C<sub>1-10</sub>alkyl,  
-N(R<sub>3</sub>)-C(O)-C<sub>1-10</sub>alkyl,  
-N<sub>3</sub>,  
aryl,  
heteroaryl,  
heterocyclyl,

-C(O)-aryl, and  
-C(O)-heteroaryl;

wherein:

Y is -O- or -S(O)<sub>0.2</sub>-; and

R<sub>3</sub> is selected from the group consisting of:

hydrogen,  
C<sub>1-10</sub>alkyl, and  
C<sub>2-10</sub>alkenyl; and

R<sub>9</sub> is selected from the group consisting of hydrogen and alkyl;  
or a pharmaceutically acceptable salt thereof.

9. (original) The compound or salt of claim 3 wherein R<sub>A'</sub> and R<sub>B'</sub> are independently selected from the group consisting of hydrogen and alkyl.

10. (canceled)

11. (currently amended) The compound or salt of ~~any one of claims 2 or 4 through 8~~ wherein n is 0.

12. (currently amended) The compound or salt of ~~any one of claims 1 through 4, 9, or 10, or claim 11 as dependent on either of claims 2 or 4,~~ wherein Z is -C(O)-.

13-14 (canceled)

15. (currently amended) The compound or salt of claim ~~14~~7 wherein R<sub>1,3</sub> is alkyl, or the R<sub>1,3</sub> groups join to form a 5-membered ring.

16. (canceled)



17. (currently amended) The compound or salt of ~~any one of claims 1 through 4, 7, 9, or 10, or claim 11 as dependent on any one of claims 2, 4, or 7, or claims 14 through 16,~~ wherein each Q is -O-.

18. (currently amended) The compound or salt of ~~any one of claims 1 through 5, 9, or 10, or claim 11 as dependent on any one of claims 2, 4, or 5, or claim 12,~~ wherein  $R_{1-1}$  is selected from the group consisting of aryl, alkyl, and  $-N(CH_3)OCH_3$ .

19. (currently amended) The compound or salt of ~~any one of claims 1 through 5, 7, 9, 10, or claim 11 as dependent on any one of claims 2, 4, 5, or 7, or claim 12, or claims 14 through 17,~~ wherein  $R_{1-1}$  is selected from the group consisting of alkyl, aryl, and hydrogen.

20. (currently amended) The compound or salt of ~~any one of claims 1 through 5, 7 through 10, or claim 11 as dependent on any one of claims 2, 4, 5, 7, or 8, or claim 12, or claims 14 through 19,~~ wherein X is a  $C_{1-6}$  alkylene or  $-(CH_2)_{2,4}-O-(CH_2)_{1,3}-$ .

21. (original) The compound or salt of claim 20 wherein X is selected from the group consisting of  $-(CH_2)_{1-6}-$ ,  $-CH_2-C(CH_3)_2-$ ,  $-(CH_2)_2-O-CH_2-$ ,  $-(CH_2)_3-O-CH_2-$ , and  $-CH_2-C(CH_3)_2-CH_2-$ .

22. (currently amended) The compound or salt of ~~any one of claims 1 through 7, 9, or 10; or claim 11 as dependent on any one of claims 2, or 4 through 7; or claims 12 through 19; or claim 20 as dependent on any one of claims 1 through 5, 7, 9, 10, or claim 11 as dependent on any one of claims 2, 4, 5, or 7, or claims 14 through 19; or claim 21 as dependent on any one of claims 1 through 5, 7, 9, 10, or claim 11 as dependent on any one of claims 2, 4, 5, or 7, or claims 14 through 19,~~ wherein  $R_{1-1}$  is selected from the group consisting of alkyl and aryl.

23. (original) The compound or salt of claim 22 wherein  $R_{1-1}$  is selected from the group consisting of methyl, ethyl, *n*-propyl, isopropyl, cyclopropyl, *n*-butyl, *sec*-butyl, isobutyl, *tert*-butyl, *n*-pentyl, cyclopentyl, *n*-hexyl, cyclohexyl, phenyl, 4-chlorophenyl and 2,4-dichlorophenyl.

24. (canceled)

25. (currently amended) The compound or salt of ~~any one of claims 1 through 24~~ wherein R<sub>2</sub> is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, and alkoxyalkyl.

26. (original) The compound or salt of claim 25 wherein R<sub>2</sub> is selected from the group consisting of hydrogen, hydroxymethyl, methyl, ethyl, *n*-propyl, *n*-butyl, ethoxymethyl, and 2-methoxyethyl.

27-28 (canceled)

29. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of ~~any one of claims 1 through 28~~ in combination with a pharmaceutically acceptable carrier.


30. (currently amended) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of ~~any one of claims 1 through 28~~ to the animal.

31. (currently amended) A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of ~~any one of claims 1 through 28~~ to the animal.

32. (currently amended) A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of ~~any one of claims 1 through 28~~ to the animal.

33-35 (canceled)

36. (new) The compound or salt of claim 2 wherein X is a C<sub>1-6</sub> alkylene or



37. (new) The compound or salt of claim 36 wherein X is selected from the group consisting of  $-(\text{CH}_2)_{1,6}\text{-}$ ,  $-\text{CH}_2\text{-C(CH}_3\text{)}_2\text{-}$ ,  $-(\text{CH}_2)_2\text{-O-CH}_2\text{-}$ ,  $-(\text{CH}_2)_3\text{-O-CH}_2\text{-}$ , and  $-\text{CH}_2\text{-C(CH}_3\text{)}_2\text{-CH}_2\text{-}$ .
38. (new) The compound or salt of claim 2 wherein  $\text{R}_{1,1}$  is selected from the group consisting of alkyl and aryl.
39. (new) The compound or salt of claim 38 wherein  $\text{R}_{1,1}$  is selected from the group consisting of methyl, ethyl, *n*-propyl, isopropyl, cyclopropyl, *n*-butyl, *sec*-butyl, isobutyl, *tert*-butyl, *n*-pentyl, cyclopentyl, *n*-hexyl, cyclohexyl, phenyl, 4-chlorophenyl and 2,4-dichlorophenyl.
40. (new) The compound or salt of claim 2 wherein  $\text{R}_2$  is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, and alkoxyalkyl.
41. (new) The compound or salt of claim 40 wherein  $\text{R}_2$  is selected from the group consisting of hydrogen, hydroxymethyl, methyl, ethyl, *n*-propyl, *n*-butyl, ethoxymethyl, and 2-methoxyethyl.
42. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 2 in combination with a pharmaceutically acceptable carrier.
43. (new) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 2 to the animal.
44. (new) The compound or salt of claim 3 wherein X is a  $\text{C}_{1,6}$  alkylene or  $-(\text{CH}_2)_{2,4}\text{-O-(CH}_2\text{)}_{1,3}\text{-}$ .
45. (new) The compound or salt of claim 3 wherein  $\text{R}_{1,1}$  is selected from the group consisting of alkyl and aryl.

46. (new) The compound or salt of claim 3 wherein  $R_2$  is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, and alkoxyalkyl.
47. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 3 in combination with a pharmaceutically acceptable carrier.
48. (new) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 3 to the animal.
49. (new) The compound or salt of claim 7 wherein  $n$  is 0.
50. (new) The compound or salt of claim 7 wherein  $X$  is a  $C_{1-6}$  alkylene or  $-(CH_2)_{2-4}-O-(CH_2)_{1-3}-$ .
51. (new) The compound or salt of claim 7 wherein  $R_2$  is selected from the group consisting of hydrogen, alkyl, hydroxyalkyl, and alkoxyalkyl.
52. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 7 in combination with a pharmaceutically acceptable carrier.
53. (new) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 7 to the animal.
54. (new) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 8 in combination with a pharmaceutically acceptable carrier.
55. (new) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 8 to the animal.